Preventing HER2 degradation improves efficacy of trastuzumab deruxtecan
Author:
- 29 January 2026
- journal article
- editorial
- Published by Springer Nature in Nature Cancer
- Vol. 7 (2) , 251-253
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecanNature Cancer, 2026
- Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)Nature Communications, 2025
- Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialThe Lancet Oncology, 2024
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerNew England Journal of Medicine, 2022
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric CancerNew England Journal of Medicine, 2020
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerNew England Journal of Medicine, 2020
- Liver injury associated with ketoconazole: Review of the published evidenceThe Journal of Clinical Pharmacology, 2014
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001